{"id":24999,"date":"2021-08-18T13:55:38","date_gmt":"2021-08-18T12:55:38","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&p=24999"},"modified":"2021-09-06T15:28:37","modified_gmt":"2021-09-06T14:28:37","slug":"jeffrey-cummings-eaic-2021-aducanumab-for-the-treatment-of-early-alzheimers-disease","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/alzheimers-disease-dementia\/conference-hub\/jeffrey-cummings-eaic-2021-aducanumab-for-the-treatment-of-early-alzheimers-disease\/","title":{"rendered":"Jeffrey Cummings, AAIC 2021: Aducanumab for the Treatment of Early Alzheimer\u2019s Disease"},"content":{"rendered":"

touchNEUROLOGY joins Jeffrey Cummings<\/strong> (University of Nevada, Las Vegas, NV, USA) at AAIC 2021 to discuss the EMERGE clinical trial findings and what this means for the use of aducanumab on the treatment of patients with Alzheimer\u2019s disease.<\/p>\n

The abstract entitled “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer\u2019s disease following treatment with high-dose aducanumab in the Phase 3 study EMERGE” was presented at the Alzheimer’s Association International Conference (AAIC) 2021, 26th-30th July 2021.<\/p>\n

ClinicalTrials.gov Identifier: NCT02484547<\/p>\n

Questions<\/strong><\/p>\n

    \n
  1. Could you give us a brief overview of the clinical development of aducanumab in patients with early Alzheimer\u2019s disease? (00:18)<\/li>\n
  2. What was the rationale for this item-level analysis of clinical measures in the EMERGE clinical trial? (01:30)<\/li>\n
  3. Which domains were analysed and what were the findings? (03:17)<\/li>\n
  4. What have we learned from these findings and what were the conclusions of the investigators? (04:37)<\/li>\n
  5. What will be the clinical impact of aducanumab on the treatment of patients with Alzheimer\u2019s disease, and what does the future hold? (05:34)<\/li>\n<\/ol>\n

    Disclosures<\/strong>: Jeffrey Cummings has provided consultation to AB Science, Acadia, Alkahest, AlphaCognition, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Biohaven, Cassava, Cerecin, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, LSP, Merck, Novo Nordisk, Oligomerix, Ono, Otsuka, PRODEO, ReMYND, Renew, Resverlogix, Roche, Signant Health, Suven, United Neuroscience, and Unlearn AI pharmaceutical, assessment, and investment companies. Jeffrey Cummings owns the copyright of the Neuropsychiatric Inventory; and is supported by Alzheimer\u2019s Drug Discovery Foundation (ADDF), NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053, and NIA grant R35AG71476.<\/p>\n

    Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/p>\n

    Filmed in coverage of the Alzheimer’s Association International Conference (AAIC) 2021.<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    touchNEUROLOGY joins Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) at AAIC 2021 to discuss the EMERGE clinical trial findings and what this means for the use of aducanumab on the treatment of patients with Alzheimer\u2019s disease. The abstract entitled “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer\u2019s disease following treatment […]<\/p>\n","protected":false},"featured_media":24995,"template":"","class_list":["post-24999","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-alzheimers-disease-dementia","video_categories-aaic-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/24999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/24999\/revisions"}],"predecessor-version":[{"id":25444,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/24999\/revisions\/25444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/24995"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=24999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}